Key facts
- This page summarizes Alison L. Hannah's Form 4 filing for CytomX Therapeutics, Inc. (CTMX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 21 Jul 2022, 16:09.
Alison L. Hannah - 19 Jul 2022 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- CTMX
- Reported as of
- 19 Jul 2022
- Net transaction value
- -$7,965
- SEC form
- 4
- Accepted by SEC
- 21 Jul 2022, 16:09:25 UTC
- Prior SEC filing
- 14 Jun 2022
- Next SEC filing
- 12 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lloyd Rowland, as Attorney-in-Fact for Alison L. Hannah
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Alison L. Hannah filed Form 4 for CytomX Therapeutics, Inc. (CTMX) on 21 Jul 2022.
Change
- Previous filing in this sequence was filed on 14 Jun 2022.
- Current net transaction value: -$7,965.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CTMX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +15,000
- Change %
- +67%
- Price
- $0.000000
- Shares after
- 37,500
- Date
- 19 Jul 2022
- Ownership
- Direct
- Footnotes
- F1, F2
CTMX
transaction
Common Stock
Sale
- Transaction value
- $7,965
- Shares
- -5,602
- Change %
- -15%
- Price
- $1.42
- Shares after
- 31,898
- Date
- 20 Jul 2022
- Ownership
- Direct
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested.
Footnote F2
Includes 22,500 restricted stock units.
Footnote F3
The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer.